PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL
SIREN : 528061153
Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2010-10-25 (15 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAUVE (30610), Gard
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL : revenue, balance sheet and financial ratios
PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL is a French company
founded 15 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAUVE (30610),
this company of category PME
shows in 2016 a revenue of 1.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL (SIREN 528061153)
Indicator
2024
2023
2021
2020
2019
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
1 208 541 €
Net income
91 662 €
79 814 €
103 325 €
64 062 €
31 718 €
71 065 €
43 320 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
66 583 €
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
3.6%
Revenue and income statement
In 2024, PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL generates positive net income of 92 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 43 k€ -> 92 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
91 662 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 18%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 71%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
18.291%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
70.796%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2023
2024
Debt ratio
204.725
165.376
124.468
106.074
63.264
33.188
18.291
Financial autonomy
28.415
32.348
37.839
39.482
49.223
63.771
70.796
Repayment capacity
20.963
None
None
None
None
None
None
Cash flow / Revenue
2.798%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
18.292024
2021
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good-14 pts over 3 years
In 2024, the debt ratio of PHARMACIE DE LA FOURCHE-D... (18.29) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
70.8%2024
2021
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+20 pts over 3 years
In 2024, the financial autonomy of PHARMACIE DE LA FOURCHE-D... (70.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 155.25. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
155.254
Liquidity indicators evolution PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2019
2020
2021
2023
2024
Liquidity ratio
145.026
151.403
155.567
156.818
133.365
164.977
155.254
Interest coverage
26.555
None
None
None
None
None
None
Sector positioning
Liquidity ratio
155.252024
2021
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average+13 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE DE LA FOURCHE-D... (155.25) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2023
2024
Operating WCR
152 457 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
45
0
0
0
0
0
0
Customer payment term (days)
5
0
0
0
0
0
0
Supplier payment term (days)
52
0
0
0
0
0
0
Positioning of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL is estimated at
1 279 669 €
(range 891 141€ - 1 914 458€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
891k€1279k€1914k€
1 279 669 €Range: 891 141€ - 1 914 458€
NAF 5 année 2024
Valuation method used
Net Income Multiple
91 662 €
×
14.0x
=1 279 669 €
Range: 891 141€ - 1 914 458€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL with other companies in the same sector:
Frequently asked questions about PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL
What is the revenue of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL ?
The revenue of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL in 2016 is 1.2 M€.
Is PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL profitable?
Yes, PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL generated a net profit of 92 k€ in 2024.
Where is the headquarters of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL ?
The headquarters of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL is located in SAUVE (30610), in the department Gard.
Where to find the tax return of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL ?
The tax return of PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL operate?
PHARMACIE DE LA FOURCHE-DOCTEUR FLORENCE LOPEZ-TROMEL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart